

Good Planning Avoids Costly Mistakes with Medical Devices and Medical Device Software

by David A. Vogel, Ph. D.
Intertech Engineering Associates, Inc.

as published in *ECN*,
November, 2005



Good engineering practice, camouflaged as regulations as defined by the FDA, will result in safe and effective medical devices and medical device software. The FDA regulating the medical device industry mandates design control and validation, both of which play an integral part in good engineering planning.

How do some medical device firms manage to trip over their own feet? Let us count the ways: trying to get away with “good enough,” leaving risk management and verification & validation for later, and earning a reputation for sloppy work.

Since everyone is a patient eventually, no one wants to believe that medical devices are subject to the same design and implementation flaws that sometimes plague other electronics and software. To prevent that, the U.S. Food and Drug Administration (FDA) regulates the medical device industry. The regulatory power ranges from pre-market notification and approval of medical devices to compliance with regulations for the design process itself.

Under its Quality System Regulations to assure safe and effective devices, the FDA requires “design controls” and “validation” as part of the

product-development process. These are really nothing more than good engineering practice camouflaged as regulations. These practices enable medical device manufacturers to enjoy the benefits of a well-defined engineering process: shorter time to market, more-maintainable and more reliable products.

FDA statistics show that 90 percent of all software-related product recalls are related to design

COMPANY PROFILE

Intertech Engineering Associates, Inc.

Address: 100 Lowder Brook Avenue
Suite 2500
Westwood, MA 02090
www.inea.com - (781) 801-1100

Industry: (Electro)Medical Devices

Services: Assessments
Training
Consulting
Hands-on Engineering

Skills: Product Design
Risk Management
Requirements Engineering
Electronics Development
Software Development
Software Verification and Validation
Production/Quality System Software Validation

flaws. (The remaining 10 percent had to do with managing the configuration such as shipping the incorrect version.) While electronics can fail due to the reliability, stress, and wear of individual components, field failures today are more often caused by faulty design and development. That's why regulators are so concerned with the design process and the product-validation process.

The FDA requires manufacturers to validate that a medical device's specifications conform to user needs and intended uses, and that those specifications can be consistently fulfilled. "Validation" in the FDA's definition is the entire collection of activities that provide objective evidence that a device works the way it's supposed to. Besides testing, these activities include risk analysis, risk management, configuration management, control of the design and development lifecycle, design reviews/inspections, plus verification activities at each phase of the development lifecycle.

Risk analysis and risk management activities are crucial to the design of safe devices, as detailed in industry standards such as ISO 14971. They involve identifying risks and reducing risk by reducing the potential severity or probability of a failure by engineering risk control measures into the product design. This process iterates until the residual risks are reduced to an acceptable level.

The biggest mistake a medical device designer can make involves the engineering process and regulatory control of the design and development process. It's also the easiest mistake to avoid.

Many medical device companies are staffed with engineers from non-medical device industries who aren't convinced that the engineering process for medical devices really does need to be strictly defined and followed. Unfortunately, when design controls are ignored, the lack of

process and control negatively impacts the quality of a design. Risks taken with the quality of the device translate to risks for the end users.

Design engineers sometimes resist a well-defined development lifecycle with scheduled reviews. They refuse to design products through requirements and specifications, and insist on composing at the keyboard as they start writing software or designing circuits on the first day of the project. This disorganized lack of process is destined to many iterations as the design narrows on the final solution and makes verification and validation by independent testers nearly impossible. The regulatory requirements are good engineering practice! They not only satisfy regulatory compliance, but also produce better-quality, more maintainable products faster.

Often, other engineering groups follow the initial "random walk" approach. Near the end of the project, quality and regulatory engineers descend to prepare documentation for submitting the device to the FDA. If a process was not predefined or was not followed, they "retro-document" the project to make it look like it was managed under well-defined design controls. The engineers resent this phase and consider all the documentation a waste of time. They're right! If designs are not created from requirements, or if software and circuits aren't implemented from designs, then the value of having those documents (for other than regulatory purposes) has passed.

Too often, there is a flurry of activity at the end of a project. The one and only design review is hastily organized. An afternoon-long Failure Modes and Effects Analysis (FMEA) meeting is held to satisfy risk management requirements. The "final release" is handed off for some quick testing so the product can get to market. Packing all these activities in at the end of the project to satisfy the regulations

simply ignores the intent of the regulation: to improve the quality of the product. All three of these activities (reviews, risk management, and verification testing) should be taking place during all phases of the development lifecycle.

Engineering quality is seldom more critical than in medical devices. A failure in the quality of the system can lead to harm for patients and other users. Recalls can damage the credibility of the company and cost millions. Regulatory action against a company can include fines, additional controls on the company, loss of time and extra costs while processes are implemented after the fact. They can even include personal fines and jail time for individuals found to intentionally disregard

the regulations, alter records or data, or cover up infractions.

The medical device business is a serious business and the FDA won't tolerate violations. Get to know the regulatory requirements and comply with them. Remember, it could be you, your spouse, your parents or children who will need that device someday. Following a controlled process makes both engineering and business sense—and is simply the right thing to do.

INSPECTIONS

Inspections are normal and can be randomly scheduled, or pre-scheduled. If you have repeat problems, you can expect more inspections.

FORM 483

This is the form to record "inspectional observations". The observations are deficiencies that must be corrected. Companies are not required to respond, but would be well advised to do so to inform the FDA of corrective and preventive actions to correct the

WARNINGS

More serious than 483's, Warnings have been reviewed at district and national level. The FDA gives very limited time to correct any issues. Responses to Warnings are required, and are typically very detailed in their explanations of corrective and preventive measures.

CONSENT DECREE

Consent decrees are enforceable by federal courts, and typically include fines, inspection cost reimbursements, detailed schedules for compliance, and additional penalties for non-compliance. This status with the FDA is semi-permanent, but can be changed via petition. Companies under consent decree can expect much extra attention from the FDA.

CRIMINAL PROSECUTION

Sometimes it does get personal. Personal charges can and have been filed in instances of gross negligence on the part of individuals, or cases of fraud where individual employees are guilty of falsifying data, lying to inspectors, hiding facts or otherwise covering up deficiencies, whether those deficiencies originally were intentional or unintentional. Employees found guilty of these charges may face fines, prison time, or both.

Poor engineering process can violate federal regulations that are enforced by the FDA. Here's a simplified escalation path the FDA can pt into action when medical device companies violate the regulations.

ABOUT THE AUTHOR:



David Vogel is the founder and president of Intertech Engineering Associates, Inc.

Dr. Vogel was a participant in a joint AAMI/FDA workgroup to develop a standard for Critical Device Software Validation which was subsequently included in the IEC 62304 Software Lifecycle Standard. He was also a participant on

the joint AAMI/FDA workgroup to develop a Technical Information Report (TIR) for Medical Device Software Risk Management. Currently, Dr. Vogel is a member of the AAMI/FDA workgroup developing a TIR on Quality System Software Validation.

A frequent lecturer for workshops and seminars on topics related to medical device development and validation, Dr. Vogel also is the author of numerous publications and holds several patents.

Dr. Vogel received a bachelor's degree in electrical engineering from Massachusetts Institute of Technology. He earned a master's degree in biomedical engineering, a master's degree in electrical and computer engineering, and a doctorate in biomedical engineering from the University of Michigan.

Intertech Service Offerings:

Risk Analysis and Management
Software Design and Development
Electronic Design and Development
Requirements Development and Management
Documentation and Traceability
Verification and Validation
Evaluations, Reviews, Inspections
Planning
Project Management
Compliance Consulting and Training
Manufacturing and Quality System Software Validation

Leverage INTERTECH's expertise to:

Reduce Project Risk

Shorten Time to Market

Cut Development and Test Cost

Assure Quality Products

ABOUT INTERTECH:

Intertech Engineering Associates has been helping medical device manufacturers bring their products to market since 1982. Through a distinct top-down service model, Intertech offers high-level consulting and hands-on engineering. By balancing technical expertise and practical business experience, we support clients through all phases of product development. While we do make your job easier, Intertech exists not to replace but to partner with clients to help balance the concerns of quality, time and cost.

With considerable experience in FDA regulatory compliance, our time-tested development process can anticipate and solve problems inexpensively on the planning board rather than through costly solutions later in the development, test, or post-deployment phases. By using deliberate processes, Intertech ensures an improvement in quality and can build client expertise.

Call us today for more information or a free consultation at 781.801.1100

INTERTECH Engineering Associates, Inc.

100 Lowder Brook Drive Suite 2500 Westwood, MA 02090 USA

www.inea.com - info@inea.com - Tel: (781) 801-1100 - Fax: (781) 801-1108